ArticleThe Journal of allergy and clinical immunology2026
Impaired CC16-mediated host responses to rhinovirus in nasal epithelial cells from patients with asthma.
Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRhinovirus (RV) infections increase the risk for developing asthma and are the major trigger for disease exacerbations. CC16 levels are decreased in patients with asthma and inversely associated with inflammation and exacerbation frequency.
objectiveWe sought to determine the impact of CC16 on the RV species A, type 1B (RV-A1B) infection in airway nasal epithelial cells in the context of asthma status.
methodsHuman nasal epithelial cells (HNECs) from participants with asthma and non-asthmatic participants in air-liquid interface culture were infected with RV-A1B, with and without recombinant CC16 (rCC16). Viral RNA and expression of host factors previously identified as associated with CC16 levels, including lysozyme, SPLUNC1, lactotransferrin, and surfactant protein D, were quantified by quantitative RT-PCR. Animal models and mouse tracheal epithelial cells (MTECs) sufficient and deficient in CC16 were infected with RV-A1B, with and without rCC16, to verify findings.
resultsHNECs from participants with asthma (n = 7) had lower gene expression of CC16 and associated host defense factors under baseline conditions compared with HNECs from non-asthmatic participants (n = 7). Whereas RV infection increased host factors in HNECs from non-asthmatic participants, HNECs from participants with asthma failed to upregulate host factors in response to RV. rCC16 induced the expression of the host defense factors and reduced viral burden in HNECs from both non-asthmatic participants and participants with asthma, which was partly dependent on integrin α2β1, or VLA-2, interactions. CC16-deficient (CC16
conclusionsResults suggest that CC16 reduces RV infection in epithelial cells by mediating the upregulation of host defense factors and that this mechanism may be defective in patients with asthma who have low levels of CC16.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.